Search results
Results from the WOW.Com Content Network
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [ 8 ] [ 9 ] Epoetin alfa is an erythropoiesis-stimulating agent. [ 8 ]
[5] [6] They work similar to naturally occurring erythropoietin. [1] They were first approved for medical use in the United States in 1989. [5] It is on the World Health Organization's List of Essential Medicines. [7] Commercially available agents include epoetin alfa and darbepoetin alfa, and biosimilars.
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin .
The EMA has granted marketing authorizations for more than 50 biosimilars since 2006. ... Epoetin alfa: Eprex/Erypo: Abseamed, [60] Binocrit, [61] Epoetin Alfa Hexal ...
Continuous erythropoietin receptor activator; D. Darbepoetin alfa; E. Epoetin alfa; Epoetin beta; M. Methoxy polyethylene glycol-epoetin beta
Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count. [21] Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause. [21]
After successful tests on patients undergoing dialysis, Epoetin alfa, marketed by Amgen under the trade name Epogen starting in 1989, became a financial success, generating a billion-dollar market for Amgen and other companies that had developed their own versions of erythropoietin, though Goldwasser would say that "the enormous clinical ...